Stockwatch: Fifty shades of fail
This article was originally published in Scrip
Executive Summary
While stock market analysts ponder the reasons for the current low volatility of broad market stock indices like the S&P500 and rising stock prices, against the backdrop of what the bond market suggests will be a partial dissolution of the Euro, investors in some biotechnology stocks do not seem to be asking any questions before parting with their money.